Terminated PHASE1 INTERVENTIONAL 2-arm NCT01517165

Pioglitazone to Treat Opioid Withdrawal Symptoms

Pioglitazone as an Aid During Buprenorphine Taper

Sponsor: National Institute on Drug Abuse (NIDA)

Updated 8 times since 2017 Last updated: Jul 3, 2018 Started: Jan 4, 2012 Primary completion: Feb 2, 2015 Completion: Feb 2, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from National Institute on Drug Abuse (NIDA)

See all terminations from National Institute on Drug Abuse (NIDA)

Other Opioid-Related Disorders trials with similar outcome

Browse all Opioid-Related Disorders trials

Listed as NCT01517165, this PHASE1 trial focuses on Opioid-Related Disorders and remains terminated or withdrawn. Sponsored by National Institute on Drug Abuse (NIDA), it has been updated 8 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Aug 2018 — Jan 2021 [monthly]

Terminated PHASE1
Jun 2018 — Aug 2018 [monthly]

Terminated PHASE1

▶ Show 3 earlier versions

May 2018 — Jun 2018 [monthly]

Terminated PHASE1
Feb 2017 — May 2018 [monthly]

Terminated PHASE1
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute on Drug Abuse (NIDA)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States